Current Report Filing (8-k)
February 16 2021 - 06:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 16,
2021
INMED PHARMACEUTICALS
INC.
(Exact Name of Company as Specified in Charter)
|
British Columbia |
|
001-39685 |
|
98-1428279 |
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
Vancouver, B.C.
Canada
|
|
V6C 1B4 |
| (Address of Principal Executive
Offices) |
|
(Zip Code) |
Company’s telephone number, including area code: (604)
669-7207
Not applicable
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each
class |
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered |
| Common Shares, no par value |
|
INM |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD Disclosure.
On February 16, 2021, the Company issued a press
release announcing the closing of a previously announced
US$4.5 million private placement. A copy of the press
release is furnished as Exhibit 99.1 hereto and is
incorporated herein by reference.
The information set forth in this Item 7.01, including Exhibit
99.1, is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section. The information set forth in this Item
7.01, including Exhibit 99.1, shall not be deemed incorporated by
reference into any other filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
Item 9.01.
Financial Statements and
Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not
filed:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
INMED PHARMACEUTICALS
INC. |
| |
|
|
| Date: February 16,
2021 |
By: |
/s/ Bruce Colwill |
| |
|
Bruce Colwill |
| |
|
Chief Financial
Officer |
2
